HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix Figures All Versions of this Article: db07-1639v1 db07-1639v2 57/5/1331    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kim, S.-J. Articles by McIntosh, C. H. S. Search for Related Content PubMed PubMed Citation Articles by Kim, S.-J. Articles by McIntosh, C. H. S. Social Bookmarking                What's this?

Inhibition of Dipeptidyl Peptidase IV (DPP-IV) with Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin (STZ)-induced Diabetic Mice

From the Department of Cellular & Physiological Sciences and the Diabetes Research Group, Life Sciences Institute ¹, University of British Columbia, 2350 Health Sciences Mall
the Department of Medicine², Vancouver, B.C., V6T 1Z3, Canada

Objective: Dipeptidyl peptidase-4 (DPP-IV) inhibitors have been introduced as therapeutics for type 2 diabetes (T2DM). They partially act by blocking degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thus increasing circulating levels of active hormones. In addition to their insulinotropic actions, GLP-1 and GIP also promote β-cell proliferation and survival, and DPP-IV inhibitors exert similar effects in rodent T2DM models. The study objective was to establish whether DPP-IV inhibitor treatment prolonged survival of transplanted islets and to determine whether positron emission tomography (PET) was appropriate for quantifying the effect of inhibition on islet mass.

Research Design and Methods: Effects of the DPP-IV inhibitor MK0431 (sitagliptin) on glycemic control and functional islet mass in a streptozotocin (STZ)-induced type 1 diabetes (T1DM) mouse model was determined with metabolic studies and microPET imaging.

Results: The T1DM mouse model exhibited elevated plasma DPP-IV levels that were substantially inhibited in mice on an MK0431- diet. Residual β-cell mass was extremely low in STZ-diabetic mice and, although active GLP-1 levels were increased by the MK0431 diet, there were no significant effects on glycemic control. Following islet transplantation, mice fed normal diet rapidly lost their ability to regulate blood glucose, reflecting the sub-optimal islet transplant. By contrast, the MK0431 group fully regulated blood glucose throughout the study and PET imaging demonstrated a profound protective effect of MK0431 on islet graft size.

Conclusions: Treatment with DPP-IV inhibitor can prolong islet graft retention in an animal model of T1DM.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?